Author Topic: RTRX - Retrophin  (Read 4396 times)

Vish_ram

  • Sr. Member
  • ****
  • Posts: 323
RTRX - Retrophin
« on: May 30, 2014, 04:20:51 AM »
This is a company Gio might love.

Martin Shkreli is the CEO and founder. It has had a controversial beginnings with going public from a reverse merger. The CEO is young, brash with a terrific record in a biotech hedge fund. He has earned the wrath of many biotech investors by going short. His record is here http://seekingalpha.com/author/martin-shkreli/instablog

He calls RTRX a M&A company. He has bought companies in quick succession. The PR http://finance.yahoo.com/news/retrophin-enters-u-license-agreement-204100983.html . If the forecasts become true, it will trade at a P/E multiple of 10 or less.

Shkreli is young (31), brilliant, hungry and raring to go. this article sums up everything about him. He has the unique experience of being in hedge fund, and now in operations. He doesn't court sell side analysts.

http://www.businessweek.com/articles/2014-04-17/retrophins-martin-shkreli-the-biotech-short-seller-who-went-long?campaign_id=yhoo

This is a biotech and risky. But this is a co to watch. I like his strategy of acquisition, raising prices (Like Qcor's Acthar), and laser focus on rare disease areas.

His twitter posts are sometimes unprofessional (like F U). You'll hear more about him & Retrophin in the future.

Disclaimer: I've a small position
« Last Edit: May 30, 2014, 08:29:48 AM by Parsad »


Andy Dufresne

  • Full Member
  • ***
  • Posts: 152
Re: RTRX - Retrophin. Caution: Risky biotech
« Reply #1 on: May 30, 2014, 05:00:09 AM »
Thanks for this Vish_ram! Shkreli seems like a colorful guy who'd be interesting to follow ...

ItsAValueTrap

  • Hero Member
  • *****
  • Posts: 1945
    • Blog
Re: RTRX - Retrophin. Caution: Risky biotech
« Reply #2 on: May 30, 2014, 05:45:57 AM »
They used to borrow money at extremely high interest rates in the past.  Usually not a good sign.
G&A is also rather high.

Then again, Martin Shkreli seems like a maverick and he is very smart.  Even smart enough to paint the tape with insider buying.  I don't think I'd want to go long biotechs right now given the valuations.  Biotech is probably in a bubble right now.

*Disclosure:  Shorted this in the past, covered at a very small profit.  There are many better biotech shorts out there.
"It's far better to buy a wonderful company at a fair price than a fair company at a wonderful price. " -Buffett

my blog

Liberty

  • Lifetime Member
  • Hero Member
  • *****
  • Posts: 11280
  • twitter.com/libertyRPF
    • twitter.com/libertyRPF
"Most haystacks don't even have a needle." |  I'm on Twitter  | This podcast episode is a must-listen

rb

  • Hero Member
  • *****
  • Posts: 2922
Re: RTRX - Retrophin
« Reply #4 on: March 09, 2018, 09:21:43 PM »
Here's the really depressing thing.

After Liberty posted here I've read the thread. All previous posters spoke glowingly about this scumbag.

LowIQinvestor

  • Hero Member
  • *****
  • Posts: 592
Re: RTRX - Retrophin
« Reply #5 on: June 12, 2019, 09:29:56 AM »
Cuurent market Cap = $790M
Commercial portfolio generates at least $165M a year
& they have $440M in cash on balance sheet ( downside protection)

Friend at biotech fund says this is interesting risk/reward given a number of upcoming catalysts ( potential FDA approvals)

Anyone follow RTRX?




ander

  • Full Member
  • ***
  • Posts: 121
Re: RTRX - Retrophin
« Reply #6 on: June 13, 2019, 10:33:45 AM »
Cuurent market Cap = $790M
Commercial portfolio generates at least $165M a year
& they have $440M in cash on balance sheet ( downside protection)

Friend at biotech fund says this is interesting risk/reward given a number of upcoming catalysts ( potential FDA approvals)

Anyone follow RTRX?





Your friend have any idea why the stock has been lagging or why it's trading cheap on the numbers. I wonder if there is a concern if their existing revenue goes away so not really as cheap as it screens?

gfp

  • Lifetime Member
  • Hero Member
  • *****
  • Posts: 1748
Re: RTRX - Retrophin
« Reply #7 on: June 13, 2019, 10:39:57 AM »
You'll hear more about him & Retrophin in the future.

This was prescient!

given2invest

  • Lifetime Member
  • Hero Member
  • *****
  • Posts: 581
Re: RTRX - Retrophin
« Reply #8 on: June 13, 2019, 10:41:38 AM »
Cuurent market Cap = $790M
Commercial portfolio generates at least $165M a year
& they have $440M in cash on balance sheet ( downside protection)

Friend at biotech fund says this is interesting risk/reward given a number of upcoming catalysts ( potential FDA approvals)

Anyone follow RTRX?

The revs are trash.  They came from buying old drugs and hiking the prices a gazillion percent.  That's why it screens so cheap. 

Google Martin Shkreli retrophin and get out the popcorn.

The real catalysts are the upcoming trial readouts which I have no view on.




Your friend have any idea why the stock has been lagging or why it's trading cheap on the numbers. I wonder if there is a concern if their existing revenue goes away so not really as cheap as it screens?

LowIQinvestor

  • Hero Member
  • *****
  • Posts: 592
Re: RTRX - Retrophin
« Reply #9 on: June 24, 2019, 10:26:24 AM »
Potential Catalyst at the end of this week:

PDUFA date of June 30, 2019 for new,
more patient-friendly formulation of
Thiola; pending approval, the Company
expects to begin marketing the new
formulation in the second half of 2019